This week Anne Donohoe and Nick Opich talk to Dr. Joseph Tucker, CEO of Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogen therapeutics for the treatment of neuropsychiatric disorders. Dr. Tucker joins us to discuss the latest news and milestones for the company, including the selection of EB-003 as its lead candidate in its EVM 301 series, plus advice to the retail investor audience on continuing drug discovery investments in the psych space.
